Fig. 3

Combinatorial administration of adagrasib and abemaciclib increased animal survival in the KRASG12C/CDKN2A mutant SW1573 brain tumor model. A, Schematic representation of the study design. Treatment protocol involved administration of adagrasib at 75 mg/kg BID, abemaciclib at 50 mg/kg daily, or their combination via oral gavage to athymic mice with intracranially injected SW1573 cell line xenografts (n = 8/group). The treatment spanned for a total of 5 weeks. B, Bioluminescence Imaging signal detection using Aura software was performed at different time points (2, 13, 24, and 40 days) following intracranial injection. Yellow triangles indicate mice exhibiting spinal signals at pretreatment (See Supplementary Fig. 4B). C, Bioluminescence Imaging analysis at the 40-day time point. Statistical analysis revealed a significant decrease in signal for the combination and adagrasib groups compared to the vehicle group (^*, Padj < 0.05). D, Survival data were collected for each group and analyzed by Kaplan–Meier statistical analysis. ^*, Padj < 0.05; ^**, Padj < 0.005. Animals that exhibited pre-treatment spinal disease were excluded from the analysis in C and D